1. Home
  2. QURE vs ABCL Comparison

QURE vs ABCL Comparison

Compare QURE & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo uniQure N.V.

QURE

uniQure N.V.

HOLD

Current Price

$27.85

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$6.15

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QURE
ABCL
Founded
1998
2012
Country
Netherlands
Canada
Employees
248
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
QURE
ABCL
Price
$27.85
$6.15
Analyst Decision
Buy
Strong Buy
Analyst Count
14
5
Target Price
$45.00
$8.40
AVG Volume (30 Days)
1.9M
8.3M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
29.67
10.91
EPS
N/A
N/A
Revenue
$13,107,000.00
$75,128,000.00
Revenue This Year
$126.12
N/A
Revenue Next Year
$200.43
$21.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
160.56
52 Week Low
$8.73
$2.09
52 Week High
$71.50
$6.52

Technical Indicators

Market Signals
Indicator
QURE
ABCL
Relative Strength Index (RSI) 68.49 74.81
Support Level $20.20 $3.32
Resistance Level $29.03 $6.52
Average True Range (ATR) 1.74 0.46
MACD -0.17 0.12
Stochastic Oscillator 75.56 97.17

Price Performance

Historical Comparison
QURE
ABCL

About QURE uniQure N.V.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: